Overview of the Decipher® Genomic Classifier
March 9, 2023
This video provides a comprehensive overview of Decipher® Prostate, a genomic test used to personalize treatment for prostate cancer. In diagnosing prostate cancer, doctors traditionally assess the risk of the disease spreading based on three factors: the amount of disease in the prostate, the Gleason score, and a PSA blood test. However, these factors may lead to over or under-treatment of individual patients. Decipher® Prostate looks beyond these standard risk determinants by analyzing the cancer's individual genes to assess its behavior, allowing for more tailored treatment decisions. Performed on a specimen from a prostate biopsy or surgery, the test provides a score that represents the aggressiveness of the cancer. The score helps in modifying treatment recommendations, potentially leading to earlier intervention or less overall treatment, depending on the results.
Related Content:
Integrating the Use of Prostate Genomic Classifiers into Clinical Practice - A Clinical Pathway Approach - Katie Murray and Anne Lizardi-Calvaresi
Transcriptome-Based Prognostic and Predictive Biomarker Analysis - The DECIPHER Genomic Classifier for Prostate Cancer - Ashley Ross
The Use of Genomics in Unfavorable Intermediate-risk Prostate Cancer - David Morris
Integrating the Use of Prostate Genomic Classifiers into Clinical Practice - A Clinical Pathway Approach - Katie Murray and Anne Lizardi-Calvaresi
Transcriptome-Based Prognostic and Predictive Biomarker Analysis - The DECIPHER Genomic Classifier for Prostate Cancer - Ashley Ross
The Use of Genomics in Unfavorable Intermediate-risk Prostate Cancer - David Morris
Read the Full Video Transcript
Speaker: This video is an overview of Decipher Prostate, a test for people with prostate cancer that can help personalize treatment. At the time of a new prostate cancer diagnosis, most cancers are contained with no spread beyond the prostate. However, some men have an increased risk of the disease progressing and spreading outside the prostate. Currently, doctors estimate a patient's risk of prostate cancer spreading by factors that include the amount of disease in the prostate, how aggressive the cancer appears to be, known as the Gleason score, and the results of a simple blood test called PSA. Patients are assigned to a risk group mostly based on these three factors.
Key questions such as who to treat, when to treat, and how aggressively to treat are not always clear from individual to individual. This means that some people may be either over or undertreated. Now, doctors can tailor treatment decisions with results from a genomic test called Decipher Prostate, which looks at a cancer's individual genes to determine its behavior. The test looks beyond standard risk defined by Gleason score and PSA to help doctors and patients make personalized treatment decisions based on a cancer behaving more or less aggressively. The test is performed on a specimen collected from the prostate biopsy or from surgery to remove the prostate.
No additional samples or procedures are required for testing. The test results provide a score from zero to one, where a lower score represents less aggressive cancer and a higher score represents more aggressive cancer. Depending on the results of the Decipher Score, your doctor may modify your treatment recommendations. Sometimes patients may need earlier or intensified treatment, while others may be good candidates for monitoring or less overall treatment. Based on your clinical risk factors, your Decipher Score and your treatment goals, you and your doctor will find a personalized treatment for your prostate cancer. This is not medical advice. If you have additional questions, please contact your doctor.
Speaker: This video is an overview of Decipher Prostate, a test for people with prostate cancer that can help personalize treatment. At the time of a new prostate cancer diagnosis, most cancers are contained with no spread beyond the prostate. However, some men have an increased risk of the disease progressing and spreading outside the prostate. Currently, doctors estimate a patient's risk of prostate cancer spreading by factors that include the amount of disease in the prostate, how aggressive the cancer appears to be, known as the Gleason score, and the results of a simple blood test called PSA. Patients are assigned to a risk group mostly based on these three factors.
Key questions such as who to treat, when to treat, and how aggressively to treat are not always clear from individual to individual. This means that some people may be either over or undertreated. Now, doctors can tailor treatment decisions with results from a genomic test called Decipher Prostate, which looks at a cancer's individual genes to determine its behavior. The test looks beyond standard risk defined by Gleason score and PSA to help doctors and patients make personalized treatment decisions based on a cancer behaving more or less aggressively. The test is performed on a specimen collected from the prostate biopsy or from surgery to remove the prostate.
No additional samples or procedures are required for testing. The test results provide a score from zero to one, where a lower score represents less aggressive cancer and a higher score represents more aggressive cancer. Depending on the results of the Decipher Score, your doctor may modify your treatment recommendations. Sometimes patients may need earlier or intensified treatment, while others may be good candidates for monitoring or less overall treatment. Based on your clinical risk factors, your Decipher Score and your treatment goals, you and your doctor will find a personalized treatment for your prostate cancer. This is not medical advice. If you have additional questions, please contact your doctor.